Page 125 - Haematologica March 2020

Transfusion dose density in lower-risk MDS
References
1. Cazzola M, Malcovati L. Myelodysplastic syndromes--coping with ineffective hematopoiesis. N Engl J Med. 2005;352 (6):536-538.
2. Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clini- cal decision making. J Clin Oncol. 2005;23 (30):7594-7603.
3. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-2088.
4. de Swart L, Smith A, Johnston TW, et al. Validation of the revised international prog- nostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry. Br J Haematol. 2015;170(3):372-383.
5. ZippererE,PostJG,HerkertM,etal.Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabo- lism in patients with myelodysplastic syn- drome. Ann Hematol. 2013;92(12):1617- 1623.
6. SantiniV,GirelliD,SannaA,etal.Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PLoS One. 2011;6(8):e23109.
7. Cuijpers ML, Raymakers RA, Mackenzie MA, de Witte TJ, Swinkels DW. Recent advances in the understanding of iron over- load in sideroblastic myelodysplastic syn- drome. Br J Haematol. 2010;149(3):322-333.
8. Shenoy N, Vallumsetla N, Rachmilewitz E, Verma A, Ginzburg Y. Impact of iron over- load and potential benefit from iron chela- tion in low-risk myelodysplastic syndrome. Blood. 2014;124(6):873-881.
9. Ambaglio I, Malcovati L, Papaemmanuil E, et al. Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1. Haematologica. 2013;98(3):420-423.
10. Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med. 2005;353(11):1135-1146.
11. GattermannN,RachmilewitzEA.Ironover-
load in MDS-pathophysiology, diagnosis, and complications. Ann Hematol. 2011;90 (1):1-10.
12. Gattermann N, Finelli C, Della Porta M, et al. Hematologic responses to deferasirox therapy in transfusion-dependent patients
with myelodysplastic syndromes. Haematologica. 2012;97(9):1364-1371.
13. Ghoti H, Amer J, Winder A, Rachmilewitz E, Fibach E. Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodys- plastic syndrome. Eur J Haematol. 2007;79
(6):463-467.
14. De Souza GF, Ribeiro HL, Jr., De Sousa JC, et
al. HFE gene mutation and oxidative dam- age biomarkers in patients with myelodys- plastic syndromes and its relation to transfu- sional iron overload: an observational cross- sectional study. BMJ Open. 2015;5(4): e006048.
15. Saigo K, Takenokuchi M, Hiramatsu Y, et al. Oxidative stress levels in myelodysplastic syndrome patients: their relationship to serum ferritin and haemoglobin values. J Int Med Res. 2011;39(5):1941-1945.
16. Bulycheva E, Rauner M, Medyouf H, et al. Myelodysplasia is in the niche: novel con- cepts and emerging therapies. Leukemia. 2015;29(2):259-268.
17. de Swart L, Reiniers C, Bagguley T, et al. Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes. Haematologica. 2018;103(1):69- 79.
18. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classifi- cation of the myeloid neoplasms. Blood. 2002;100(7):2292-2302.
19. Platzbecker U, Fenaux P, Ades L, et al. Proposals for revised IWG 2018 hematolog- ical response criteria in patients with MDS included in clinical trials. Blood. 2018;133(10):1020-1030.
20. Goldberg SL, Chen E, Corral M, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010;28(17):2847-2852.
21. Hiwase DK, Singhal D, Strupp C, et al. Dynamic assessment of RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patients. Am J Hematol. 2017;92(6):508-514.
22. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolu- tion in myelodysplastic syndromes. J Clin Oncol. 2007;25(23):3503-3510.
23. Waszczuk-Gajda A, Madry K, Machowicz R, et al. Red blood cell transfusion depend- ency and hyperferritinemia are associated with impaired survival in patients diagnosed with myelodysplastic syndromes: results from the first Polish MDS-PALG registry. Adv Clin Exp Med. 2016;25(4):633-641.
24. Malcovati L, Della Porta MG, Strupp C, et al. Impact of the degree of anemia on the out- come of patients with myelodysplastic syn- drome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica. 2011;96 (10):1433-1440.
25. Gale RP, Barosi G, Barbui T, et al. What are RBC-transfusion-dependence and -indepen- dence? Leuk Res. 2011;35(1):8-11.
26. Pereira A, Nomdedeu M, Aguilar JL, et al.
Transfusion intensity, not the cumulative red blood cell transfusion burden, deter- mines the prognosis of patients with myelodysplastic syndrome on chronic trans- fusion support. Am J Hematol. 2011;86 (3):245-250.
27. Hellstrom-Lindberg E, Negrin R, Stein R, et al. Erythroid response to treatment with G- CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol. 1997;99(2):344-351.
28. Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-depen- dent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011;118(14):3765-3776.
29. Luten M, Roerdinkholder-Stoelwinder B, Schaap NP, de Grip WJ, Bos HJ, Bosman GJ. Survival of red blood cells after transfusion: a comparison between red cells concentrates of different storage periods. Transfusion. 2008;48(7):1478-1485.
30. van de Watering L, Lorinser J, Versteegh M, Westendord R, Brand A. Effects of storage time of red blood cell transfusions on the prognosis of coronary artery bypass graft patients. Transfusion. 2006;46(10):1712- 1718.
31. Hod EA, Zhang N, Sokol SA, et al. Transfusion of red blood cells after pro- longed storage produces harmful effects that are mediated by iron and inflammation. Blood. 2010;115(21):4284-4292.
32. McQuilten ZK, French CJ, Nichol A, Higgins A, Cooper DJ. Effect of age of red cells for transfusion on patient outcomes: a system- atic review and meta-analysis. Transfus Med Rev. 2018;32(2):77-88.
33. Rapido F, Brittenham GM, Bandyopadhyay S, et al. Prolonged red cell storage before transfusion increases extravascular hemoly- sis. J Clin Invest. 2017;127(1):375-382.
34. de Swart L, Hendriks JC, van der Vorm LN, et al. Second international round robin for the quantification of serum non-transfer- rin-bound iron and labile plasma iron in patients with iron-overload disorders. Haematologica. 2016;101(1):38-45.
35. Rachmilewitz EA, Weizer-Stern O, Adamsky K, et al. Role of iron in inducing oxidative stress in thalassemia: can it be pre- vented by inhibition of absorption and by antioxidants? Ann N Y Acad Sci. 2005;1054: 118-123.
36. Hershko C, Link G, Cabantchik I. Pathophysiology of iron overload. Ann N Y Acad Sci. 1998;850:191-201.
37. Hod EA, Brittenham GM, Billote GB, et al. Transfusion of human volunteers with older, stored red blood cells produces extravascular hemolysis and circulating non-transferrin- bound iron. Blood. 2011;118(25):6675-6682.
haematologica | 2020; 105(3)
639